Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF

References

• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:655–61
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [The Multiple Sclerosis Collaborative Research Group (MSCRG)]. Ann Neurol 1996;39:285–94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-in relapsing/remitting multiple sclerosis. Lancet 1998;352: 1498–504
   Google Scholar
• Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 2005;12:425–31
   PubMed Web of Science ®Google Scholar
• Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon β 1b and 1a treatment in relapsing–remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689–92
   PubMed Web of Science ®Google Scholar
• Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-tohead study. Acta Neurol Scand 2006;113:241–7
   PubMed Web of Science ®Google Scholar
• Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing– remitting multiple sclerosis: an eight year experience in a specialist multiple sclerosis centre. J Neurol 2005;252:795–800
   PubMed Web of Science ®Google Scholar
• Trojano M, Ligouri M, Paolicelli, et al. Interferon beta in relapse– remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003;9:451–7
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al.; for the EVIDENCE (EVidence of Interferon Dose–response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens inn MS. The EVIDENCE trial. Neurology 2002;59: 1496–506
   Google Scholar
• Murray TJ. Rationale and design of the Prospective and Retrospective Observational Study of Avonex and Rebif (PROOF) for the treatment of relapsing–remitting multiple sclerosis. Curr Med Res Opin 2004;20:25–30
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31
   PubMed Web of Science ®Google Scholar
• Carrá A, Onaha, P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing–remitting sclerosis. Eur J Neurol 2003;10:671–6
   Google Scholar
• Limmroth V, Malessa R, Zettl UK, et al.; for the QUASIMS Study Group. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing–remitting multiple sclerosis. J Neurol 2007;254:67–77
   Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453–60
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148–53
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Munschauer 3rd FE, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465–9
   Google Scholar
• Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon β-1a. A 4-year controlled study. Neurology 2005;65: 40–7
   Google Scholar
• Francis GS, Rice GPA, Alsop JC, for the PRISMS Study Group. Interferon β-1a in MS. Results following development of neutralizing antibodies in PRISMS. Neurology 2005;65: 48–55
   Google Scholar
• Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000;48:706–12
   PubMed Web of Science ®Google Scholar